scholarly journals Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients

1999 ◽  
Vol 48 (3) ◽  
pp. 445-448 ◽  
Author(s):  
Böttiger ◽  
Brattström ◽  
Tydén ◽  
Säwe ◽  
Groth
Keyword(s):  
Side Effects ◽  
Renal Transplant ◽  
Whole Blood ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Blood Concentrations

Steady-state concentration of cyclosporin G (OG37-325) and its metabolites in renal transplant recipients

1994 ◽  
Vol 40 (4) ◽  
pp. 613-616 ◽  
Author(s):  
L J Langman ◽  
A B Leichtman ◽  
W F Weitzel ◽  
R W Yatscoff
Keyword(s):  
Steady State ◽  
Renal Transplant ◽  
Secondary Metabolites ◽  
Whole Blood ◽  
Relative Concentration ◽  
Cross Reactivity ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Dosing Interval ◽  
Trough Concentrations

Abstract The steady-state concentrations of cyclosporin G (OG37-325) (CsG) and six of its metabolites (GM1, GM9, GM4N, GM1c, GM1c9, GM19) were measured throughout the 12-h dosing interval in six renal transplant recipients receiving CsG as prophylaxis against acute cellular rejection. The mean 12-h whole-blood trough concentrations (micrograms/L) were CsG, 131 +/- 26; GM1, 79 +/- 55; GM9, 110 +/- 114; GM4N, 28 +/- 18; GM1c, 31 +/- 18; GM1c9, 216 +/- 145; and GM19, 303 +/- 217. The relative concentration of the primary metabolites (GM1, GM9, GM4N) remained stable with respect to CsG throughout the dosing interval, whereas that of the secondary metabolites increased. The secondary metabolites GM19 and GM1c9 exhibited extensive between-patient variation. We investigated the effect of these metabolites on commercially available monoclonal antibody-based fluorescence polarization immunoassays (FPIA) and RIAs adapted for measurement of CsG. The 12-h whole-blood trough concentrations measured by FPIA and RIA exceed those measured by HPLC by 19% and 36%, respectively. These measured biases corresponded closely with the calculated biases (FPIA 19%, RIA 28%) based on the known cross-reactivities of CsG metabolites and their concentrations. These results suggest that cross-reactivity with metabolites account for a large part of the bias observed in immunoassays of CsG.

scholarly journals Optimization of osteoporosis and osteopenia management among renal transplant recipients

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Mohammed K. Afifi ◽  
Ahmed S. Kenawy ◽  
Heba H. El Demellawy ◽  
Amany A. Azouz ◽  
Torki Al-Otaibi ◽  
...  
Keyword(s):  
Side Effects ◽  
Renal Transplant ◽  
Positive Impact ◽  
Renal Transplant Recipients ◽  
Close Monitoring ◽  
Transplant Recipients ◽  
Mineral Density ◽  
T Score ◽  
Spinal Osteoporosis ◽  
One Year

Abstract Background Osteoporosis and osteopenia occur frequently in renal transplant recipients due to long-term use of immune-suppressants including corticosteroids. Previous treatment options like bisphosphonates had acceptable but rather unsatisfactory results after transplant. The aim of the current study is to directly compare the efficacy of denosumab and oral ibandronate in late RTR with low bone mineral density. Results The study was conducted Iin Hamed Al-Essa Kidney transplant center, Kuwait, in 2020. The data of 52 denosumab and 48 ibandronate patients were collected at the baseline and after one year of treatment. Spine and hip T-score readings, side effects, and other laboratory results were analyzed to evaluate the use of both medications. The mean number of months after transplant was 25 (± 13.9) months. After one year of treatment, denosumab alleviated both spinal osteoporosis and osteopenia T-score values from −3.13 to −2.4 (p = 0.008) and from −1.9 to −1.5 (p = 0.015), respectively. Besides, it reduced hip osteoporosis and osteopenia insignificantly from −3.45 to −3.1 and from −1.5 to −1.3, respectively (p > 0.05). Ibandronate improved spinal osteopenia from −1.6 to −1.55 (p = 0.97) and failed to show any positive impact on other sites; the spinal osteoporosis changed from −2.8 to −3 and hip osteoporosis and osteopenia changed from −3.1 to −3.12 and from −1.4 to −1.45, respectively (p > 0.05). The use of ibandronate was more associated with gastrointestinal tract (GIT) side effects, while hypocalcemia episodes were significantly higher in the denosumab group. Conclusion Denosumab improved both spinal and hip T-score values in comparison with ibandronate in RTR. Close monitoring is required for denosumab patients to prevent the associated hypocalcemia. Graphical Abstract

scholarly journals Prediction of Cytomegalovirus (CMV) Plasma Load from Evaluation of CMV Whole-Blood Load in Samples from Renal Transplant Recipients

2007 ◽  
Vol 46 (2) ◽  
pp. 493-498 ◽  
Author(s):  
I. Garrigue ◽  
A. Doussau ◽  
J. Asselineau ◽  
H. Bricout ◽  
L. Couzi ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Whole Blood ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Plasma Load
Sign in / Sign up

Export Citation Format

Share Document